About Kashiv BioSciences
Kashiv BioSciences is a Healthcare company based in Piscataway (United States) founded in 2010 by Chintu Patel and Chirag Patel, and was acquired by Amneal in April 2026. Biosimilar medicines are developed through integrated biopharmaceutical operations. The company has 164 employees. Its chief executive, as recorded, is Sandeep Athalye. Its Indian entity Kashiv Biosciences Private Limited reported revenue of ₹252 Cr. Its focus areas include Biopharma Outsourcing, CDMO, Biologics and Mammalian Cell Line.
Company details
Kashiv BioSciences was established in 2010 and is headquartered in Piscataway, United States. As an integrated biopharmaceutical company, focus is placed on developing biosimilar medicines. Capabilities encompass research and development, clinical operations, manufacturing processes, regulatory compliance, and intellectual property management. Operations support the creation of affordable alternatives to biologic drugs within the healthcare sector.
- Headquarters Piscataway, United States
- Employees 164
- Founders Chintu Patel, Chirag Patel
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website kashivbiosciences.com
- Social LinkedIn
- Acquired by Amneal (Apr 2026)
- Legal Name Kashiv Biosciences Private Limited
- Date of Incorporation 29 Jun, 2018
- Jurisdiction Ahmedabad, Gujarat, India
Associated legal entities of Kashiv BioSciences
Kashiv BioSciences operates through Kashiv Biosciences Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Kashiv Biosciences Private Limited CIN U74995GJ2018FTC103064 | Active | 29 Jun 2018 | Ahmedabad, Gujarat | ₹252 Cr | 164 | 6 | View details |
Funding Insights of Kashiv BioSciences
- Total Rounds 1
- Last Round Debt – Conventional — $72.29M
- First Round $72.29M
(Dec 2025)
All 1 funding rounds of Kashiv BioSciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2025 | $72.29M | Debt – Conventional | – | – | – |
1 investors in total: 1 institutional.
Investors in Kashiv BioSciences
Kashiv BioSciences has secured backing from 1 investor. Prominent investors backing the company include Amneal.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Manufacturer of generics formulations | 2002 | amneal.com | Bridgewater, United States |
Investor details for Kashiv BioSciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Kashiv Biosciences Private Limited (Kashiv BioSciences)
Kashiv Biosciences Private Limited is the primary company behind Kashiv BioSciences. The board of Kashiv Biosciences Private Limited currently have 5 directors; the longest-serving is Sureshkumar Punambhai Patel, appointed in 2018. 1 earlier director has ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sureshkumar Punambhai Patel DIN 01856345 | Director | 29 Jun 2018 | 8 yrs 4 mo | Kashiv Biosciences Private Limited |
| Chinubhai Chandubhai Patel DIN 08891389 | Director | 29 Sep 2020 | 6 yrs 1 mo | Kashiv Biosciences Private Limited |
| Sandeep Radhakisan Raktate DIN 03442482 | Additional Director | 11 Aug 2026 | 2 mo | Kashiv Biosciences Private Limited |
| Rahul Maitra DIN 10624671 | Additional Director | 11 Aug 2026 | 2 mo | Kashiv Biosciences Private Limited |
| Shekhar Ramachandran DIN 11913927 | Additional Director | 25 Aug 2026 | 2 mo | Kashiv Biosciences Private Limited |
People of Kashiv BioSciences
49 people are tracked at Kashiv BioSciences (27 in leadership, 22 in team); the tracked headcount is 164.
| Name | Role | Group |
|---|---|---|
Chintu Patel | Co-Founder | Leadership |
Chirag Patel | Co-Founder | Leadership |
Sandeep Athalye | CEO & MD | Leadership |
Roshan Upadhyay | General Manager | Leadership |
Navnit Shah | President & CSO | Leadership |
Chandramauli Rawal | COO | Leadership |
Paras Vasanani | Head of BD&L, Portfolio, Strategy | Leadership |
Om Narayan | Head of Biosimilars & Vaccines | Leadership |
Mukesh Mahajan | General Manager | Leadership |
Chintan Shah | General Manager | Leadership |
Suma Poduval | Head Of Human Resources - India | Leadership |
Ritesh Gurjar | General Manager | Global Business Development Portfolio Management & Strategy | Leadership |
Mehulkumar Sharma | Vice President, Global Head Of Engineering & Facilities - Head Of Capital Projects, CQV & EHS | Leadership |
Tarun Kumar Gupta | Senior General Manager- Head Process Development R&d | Leadership |
Rajat Desai | Director Of Operations | Leadership |
Dr Chandramauli Rawal | Chief Operating Officer | Leadership |
Shalini Sharma | Vice President | Leadership |
James F Fitzpatrick | Vice President Human Resources | Leadership |
Kandarp N Raval | Associate Vice President | Leadership |
Dr. Vaibhav Dubey | Senior General Manager | Leadership |
29 more people are available in the full profile.
Complete people profiles for Kashiv BioSciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Kashiv BioSciences
Figures of Kashiv Biosciences Private Limited, the primary company behind Kashiv BioSciences, for FY 2025. Revenue was ₹252 Cr (+70% year on year). Net profit was ₹30.84 Cr (12% margin). EBITDA was ₹65.86 Cr (26% margin). Revenue has grown at a compounded annual rate of +41% over three years and +57% over five years.
- ₹252 CrRevenue · FY 2025 · +70% YoY
- ₹30.84 CrNet profit · 12% margin
- ₹65.86 CrEBITDA · 26% margin
- ₹99.05 CrPaid-up capital
- 164Employees (provident fund records)
- +41%Revenue CAGR, 3 years
- +57%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Kashiv Biosciences Private Limited are on its company page.
Detailed financial statements for Kashiv BioSciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Kashiv BioSciences
3 dated milestones of Kashiv BioSciences across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Kashiv BioSciences is founded.
- Funding First funding round of $72.3M.
- Exit Acquired by Amneal.
Web traffic of Kashiv BioSciences
The website of Kashiv BioSciences (kashivbiosciences.com) receives about 5.4K visits a month.
- Monthly visits5.4K
▲ 198.4% vs previous month
Websites whose visitors overlap most with Kashiv BioSciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| akrospharma.com | 100% | 1.5K | #10,598,752 | View details | |
| nexomics.com | 100% | 1.3K | #11,468,977 | View details | |
| raritanpharm.com | 97% | 1.8K | #11,430,509 | View details | |
| genesisbiotechgroup.com | 93% | #5,382,456 | View details | ||
| prolongpharma.com | 92% | 3.8K | #13,715,654 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 10 similar websites and full traffic analytics for Kashiv BioSciences
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Kashiv BioSciences (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kashiv Biosciences
Complete news archive for Kashiv BioSciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kashiv BioSciences
Kashiv BioSciences was founded in 2010 and raised its 1st funding round 15 years after it was founded.
Kashiv BioSciences is headquartered in Piscataway, United States. It is registered at Piscataway, New Jersey, United States.
Sandeep Athalye is the CEO of Kashiv BioSciences, as recorded in our data.
Kashiv BioSciences has 164 employees.
The primary company behind Kashiv BioSciences, Kashiv Biosciences Private Limited, reported revenue of ₹252 Cr for FY 2025, up 70% year on year.
Kashiv BioSciences was established in 2010 and is headquartered in Piscataway, United States. As an integrated biopharmaceutical company, focus is placed on developing biosimilar medicines. Capabilities encompass research and development, clinical operations, manufacturing processes, regulatory compliance, and intellectual property management. Operations support the creation of affordable alternatives to biologic drugs within the healthcare sector.
Kashiv BioSciences has 1 investor. Key investors include Amneal.
Kashiv BioSciences operates through Kashiv Biosciences Private Limited.
Yes. Kashiv BioSciences was acquired by Amneal in April 2026.
The legal entities of Kashiv BioSciences currently have 6 directors, including Sureshkumar Punambhai Patel, Nirali Maharishi Thula, Chinubhai Chandubhai Patel and others.